LINAGLIPTIN; METFORMIN HYDROCHLORIDE | N201281 | BOEHRINGER INGELHEIM PHARMACEUTICALS INC
| Trial # | Patent | Type | Petitioner | Status | Filed | Decision |
|---|---|---|---|---|---|---|
| IPR2016-01563 | 8673927 | IPR | Mylan Pharmaceuticals Inc. et al. | Terminated | 2016-08-10 | — |
| IPR2016-01564 | 8846695 | IPR | Mylan Pharmaceuticals Inc. et al. | Terminated | 2016-08-10 | — |
| IPR2016-01566 | 9173859Delisted | IPR | Mylan Pharmaceuticals Inc. et al. | Institution Denied | 2016-08-10 | — |
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Boehringer Ingelheim Pharmaceuticals Inc. et al v. Mylan Pharmaceuticals Inc. et al 1 patentANDA 208431, 208430linagliptin | WVND | 2024-08-29 | Terminated 2025-11-24 | — |
BOEHRINGER INGELHEIM PHARMACEUTICALS INC. et al v. SUN PHARMACEUTICAL INDUSTRIES LTD et al 1 patentANDA 208455, 208454linagliptin; linagliptin and metformin hydrochloride | D.N.J. | 2016-03-29 | Terminated 2016-04-19 | — |
Boehringer Ingelheim Pharmaceuticals, Inc. et al v. Mylan Pharmaceuticals Inc. et al 3 patentsANDA 208431, 208430linagliptin | WVND | 2015-08-25 | Terminated 2016-07-27 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 8673927 | May 4, 2027PED: Nov 4, 2027 | PED | — | — | Delisted | |
| 8846695 | Jun 4, 2030PED: Dec 4, 2030 | PED | — | — | — | |
| 8883805 | Nov 26, 2025PED: May 26, 2026 | PED | — | Yes | — | — |
| 9155705 | May 21, 2030PED: Nov 21, 2030 | PED | — | Yes | — | — |
| 9415016 | Apr 2, 2029PED: Oct 2, 2029 | PED | — | Yes | — | — |
| 10022379 | Apr 2, 2029PED: Oct 2, 2029 | PED | — | — | — | |
| 10973827 | Apr 2, 2029PED: Oct 2, 2029 | PED | — | Yes | — | — |
| 11911388 | Apr 10, 2030 | — | — | — | — | |
| 12364700 | Jun 8, 2037PED: Dec 8, 2037 | PED | — | — | — |
| Code | Date | Status |
|---|---|---|
| M-295 | Jun 20, 2026 | Expired |
| PED | Dec 20, 2026 | < 1 year |